Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Météoxane is a fixed-dose combination small-molecule drug developed by Laboratoires IPRAD for the symptomatic treatment of functional intestinal disorders and irritable bowel syndrome (IBS). It consists of two active ingredients: phloroglucinol (80 mg), a non-atropinergic antispasmodic that acts directly on gastrointestinal smooth muscle to relieve spasms, and simeticone (125 mg), an antiflatulent that modifies the surface tension of gas bubbles in the digestive tract to facilitate their dispersion. The drug is primarily indicated for symptoms such as bloating, flatulence, and abdominal pain. It is available over-the-counter in France as oral capsules and has been evaluated in Phase 4 clinical trials for the management of painful exacerbations in patients with IBS.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phloroglucinol + simeticone.